DUBLIN, Sept. 5, 2018 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced that the company is now
accepting applications for the 3rd annual ALKERMES
INSPIRATION GRANTS® program. The competitive
program will award up to $1 million
in grants to various organizations for the implementation of
innovative, high-impact and replicable programs designed to make a
positive difference in the lives of people affected by mental
health and substance use disorders. The application period is now
open and will run through Oct. 2,
2018.
"Addiction and mental health illnesses are the cause of a
tremendous amount of suffering—for the individuals affected
and for their families, friends and communities," said Richard
Pops, Chief Executive Officer at Alkermes. "At Alkermes, we know
that medicines are only one component of comprehensive care, and it
is our mission to be part of the broader solution—supporting
the organizations that are working on the front lines to care for
those most impacted. The ALKERMES INSPIRATION GRANTS program is
designed to provide this support. Now in our third year, we are
proud of the impact these grants are having and look forward to
supporting more of the inspiring innovation happening across the
country."
"The overwhelming number and quality of submissions we received
over the past two years demonstrated that meaningful and innovative
programs exist across the country; however, the submissions also
highlighted the significant lack of resources available to support
those with mental health conditions and substance use disorders,"
said Nikki Levy, Vice President of
Patient Engagement at Alkermes. "We hope this program will provide
needed funding for some of these programs to succeed and replicate,
building on our promise to make a difference in patients' lives
through research, development and advocacy."
Alkermes will award grants for the development or expansion of
programs to support mental health and addiction in two key areas:
improving or enhancing support or resources for people affected by
mental health or substance use disorders, and/or integrating the
perspective of people affected by mental health or substance use
disorders into drug development or care delivery. Eligible
non-profit organizations may submit applications for grants by
clicking here or visiting
www.alkermes.com/responsibility/inspiration-grants. Multiple
submissions by the same organization are permitted.
Submissions are evaluated based on a set of standard criteria
and selected by Alkermes in partnership with external reviewers who
represent the perspectives of the community. Over the past two
years, the ALKERMES INSPIRATION GRANTS program has supported the
efforts of more than two dozen organizations to continue their
important work in local communities and nationally.
"Our 2017 ALKERMES INSPIRATION GRANT made a tremendous
difference in the impact the Caregiver Action Network can make for
families affected by mental health issues. Family caregiving is
never easy and mental illness presents additional challenges. We
have always wanted to directly reach more family members of those
with mental health issues, but simply didn't have the resources,"
said John Schall, Chief Executive
Officer of Caregiver Action Network. "The ALKERMES INSPIRATION
GRANTS program allowed us to offer thousands of families practical
advice and information through our new four-part Blueprint for
Family Caregivers of Loved Ones with Mental Health Issues
electronic guidebook."
Only eligible U.S. 501(c)(3) non-profit organizations may apply.
These may include, but are not limited to, patient organizations
and professional societies. The applications close at 11:59 p.m. ET
on Oct. 2, 2018. Grants will be awarded in November and funding
will be distributed at the end of the calendar year. Historically,
the funding awarded to individual programs has ranged from $12,000
to $200,000.
For more information on the ALKERMES INSPIRATION GRANTS program,
including the application, submission instructions and evaluation
criteria, please visit www.alkermes.com/inspirationgrants.
About Alkermes plc
Alkermes plc is a fully
integrated, global biopharmaceutical company developing innovative
medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates
for chronic diseases that include schizophrenia, depression,
addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts;
a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more
information, please visit Alkermes' website
at www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. The company
cautions that forward-looking statements are inherently uncertain.
Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and they are necessarily subject to a high
degree of uncertainty and risk. Actual performance and results may
differ materially from those expressed or implied in the
forward-looking statements due to various risks and uncertainties.
These risks and uncertainties include, among others, those risks
and uncertainties described under the heading "Risk Factors" in the
company's Annual Report on Form 10-K for the year ended
December 31, 2017, Quarterly Report
on Form 10-Q for the quarter ended June 30,
2018 and in subsequent filings made by the company with the
U.S. Securities and Exchange Commission (SEC), which are available
on the SEC's website at www.sec.gov. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release.
ALKERMES INSPIRATION GRANTS® is a registered
trademark of Alkermes, Inc.
Alkermes
Contacts:
|
|
For
Investors:
|
Eva Stroynowski, +1
781 609 6823
|
|
Sandy
Coombs, +1 781 609 6377
|
For Media:
|
Sherry
Feldberg, +1 781 609 6276
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/alkermes-announces-3rd-annual-competitive-grants-program-to-support-those-affected-by-mental-health-and-substance-use-disorders-300706754.html
SOURCE Alkermes plc